Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

A summer meeting full of magical moments

In their day-to-day, everybody at Lucid Group strives to develop outstanding medical education programmes to improve patient outcomes. Over the summer, however, they like to take some time to turn...

Sir Henry presents Queen’s Award for Enterprise to Lucid Group

On 13 July, Lord Lieutenant Sir Henry presented Lucid Group with the Queen’s Award for Enterprise in International Trade. This award recognises UK-based businesses that have achieved outstanding growth overseas...

Lucid Group’s winning formula is recognised at Communiqué 2017

Lucid Group’s commitment to improving patient outcomes across the globe was recognised at the 2017 Communiqué Awards in London last night. The agency won the awards for Excellence in Communications...

Lucid Partners grows its medical writing team

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

Using insights to effect behaviour change

The days when medical communication simply aimed to raise awareness of clinical challenges are well and truly over. In recent years, we have seen a clear shift towards changing physicians’...

All five of Lucid’s entries reach the shortlist for Communiqué 2017

Lucid Group is thrilled to learn that all its entries for the 2017 Communiqué Awards have been shortlisted as finalists! The categories include: Communications Consultancy of the Year Lucid Group   Excellence in Communications via...

Your career starts here

When working in medical communications, one of the most common questions we get asked is “What is it that you actually do?” Many students and graduates are unaware of medical...

Are you suffering from templatitis?

At times, it feels like procedures are designed to frustrate, and templates often hinder rather than help. Especially in strategic planning, where a certain degree of creativity and innovation is...

It’s time to shine for Lucid’s rare disease team

No team members were getting their hands dirty today! Instead, they were treated to car valets and manicures as a thank you for all their hard work delivering a number...

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.